Teva buys rights for Israeli co Biolojic's asthma treatment

Teva's R&D labs in Netanya  credit: Teva PR
Teva's R&D labs in Netanya credit: Teva PR

Biolojic is eligible to receive tiered royalties in "mid-single to low-double digit" percentages of sales should Teva successfully commercialize a therapy.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) and Israeli company Biolojic Design have signed a collaboration agreement. Teva will complete development of Biolojic's antibody-based therapy for the treatment of asthma and atopic dermatitis (skin asthma) and have exclusive licensing rights to market the drug.

As part of the agreement, Teva will make an upfront payment and milestone payments. Biolojic is also eligible to receive tiered royalties in "mid-single to low-double digit" percentages of sales should Teva successfully commercialize the therapy. The drug is still in animal trials.

Biolojic Design founder and CEO Yanay Ofran said, "The potential therapy we designed for Atopic Dermatitis and Asthma is another example of how AI can revolutionize drug development. Biolojic’s AI platform allows us to rethink and reimagine what drugs can do. Our platform has already yielded the first AI designed antibody that entered the clinic. As Biolojic continues to focus on developing its internal fully owned pipeline, we are excited that our platform may allow Teva to develop BD9 as a novel therapeutic approach that has the potential to be best-in-class."

Biolojic Design, founded in 2009, aims to transform antibodies into intelligent medicinal solutions through AI and computational design. Biolojic’s AI platform generates computationally designed antibodies that bind to predefined epitopes, thus allowing for the design of specific functions: agonism, antagonism and selective binding..

Teva President and CEO Richard Francis said, "Our Pivot to Growth strategy is opening a new era for Teva as we step up innovation and accelerate development of novel therapies in our immunology pipeline powered both by our inherent antibody engineering capabilities and exciting partnerships. Based on the size of the indications and validity of the targets, this collaboration with Biolojic presents an incredible opportunity to bring this treatment to many patients. As BD9 can tune itself to the specific underlying conditions of the disease and potentially help more patients who do not respond to current therapies and improve outcomes for existing responders and thus addressing a large unmet need."

Published by Globes, Israel business news - en.globes.co.il - on December 14, 2023.

© Copyright of Globes Publisher Itonut (1983) Ltd., 2023.

Teva's R&D labs in Netanya  credit: Teva PR
Teva's R&D labs in Netanya credit: Teva PR
Shekel credit: Shutterstock Vladirina 32 Shekel weakens after BoI rate call

Poria Financial Planning chairman Or Poria: There is growing uncertainty over the collapse of the hostage deal, and the increasing probability of renewed fighting in the south.

Daniel Aronovitz credit: Joseph Laor Insight Partners: $6b and still investing in Israel

Insight Partners newly appointed Israel partner Daniel Aronovitz tells "Globes" about the US firms plans for Israel and reveals the huge extent of past investment.

Bank of Israel Governor Amir Yaron credit: Eyal Izhar, Tali Bogdansky BoI Governor: We hope for two rate cuts in second half

Bank of Israel Governor Prof. Amir Yaron tells "Globes" he remains concerned about inflation, higher demand than supply, and real estate balloon loans.

Bank of Israel Governor Prof. Amir Yaron credit: Yossi Cohen BoI keeps rate unchanged for ninth consecutive time

The Bank of Israel Monetary Committee reiterated: the interest rate path will be determined in accordance with the convergence of inflation to its target.

Supervisor of Banks Daniel Hahiashvili credit: Yossi Cohen Regulator opposes Israeli banks increasing dividends

Supervisor of Banks, Daniel Hahiashvili is reportedly reluctant to let banks increase their dividend distribution, from a ceiling of 40% of profits towards 50%.

Metro credit: Bar Lavi Metro dispute over station entrances to delay tenders

NTA believes stations only need one entrance while the Israel Planning Administration says several are necessary.

Declining tech industry pay  credit: Ussama Azam Unsplash Tech salaries in Israel falling with jobs harder to find

Despite inflation tech salaries are declining, the Central Bureau of Statistics reports.

Tel Aviv credit: Shutterstock New Tel Aviv master plan massively boosts building rights

The plan, set to be approved for deposit, adds 11.3 million square meters of housing, 6.1 million square meters of office space and allows construction of 80-floor buildings in certain places.

Israeli apartments Credit: Shutterstock Apartments sold and rented

A selection of recent real estate deals in Israel in Kfar Saba, Even Yehuda, Rishon Lezion, Hadera, Haifa and Tzfat.

Jerusalem's Midtown project credit: DBLD architects Foreign residents dominate Jerusalem city center housing market

Wealthy foreign residents are increasingly pricing residents out of the market in central neighborhoods, as ghost apartments haunt the city.

Egyptian tanks in Sinai near Rafah credit: Reuters Mohamed Abd El Ghany Egyptian military violations in Sinai concern Israel

President Donald Trump's relocation plan for Gazans is further straining fraught relations between Israel and Egypt. "Globes" examines whether it could spark a war.

Yitzhak Tshuva credit: Gidon Levy and Tali Bogdanovsky Isracard shareholders approve acquisition by Delek

For the deal to go through, approval is now needed from the Supervisor of Banks and the Israel Competition Authority.

Air Canada Photo: Shutterstock Air Canada to resume Israel flights in June

The Canadian airline will resume Toronto-Tel Aviv flights on June 8 and Montreal-Tel Aviv flights in August.

NICE CEO Scott Russell credit: SAP NICE Systems falls sharply on disappointing 2025 guidance

NICE sees $693-703 million revenue in the first quarter of 2025, up 6% from the corresponding quarter of 2024, with non-GAAP earnings per share of $2.78-2.88 - 3.8% below the analysts' consensus for revenue and 2.4% below for profit.

Tel Aviv credit: Shutterstock Urban renewal plan approved in heart of Tel Aviv

The plan for the Hahashmal neighborhood opposite the Old Central Bus Station includes a 30-floor tower.

Smartshooter credit: Smartshooter Germany buys Kibbutz Yagur's Smartshooter AI sights

The product family includes systems mounted on personal rifles, remotely controlled systems, and systems carried by vehicles, robots, and even drones.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018